Figure 1From: Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects Plasma concentration profiles of rHuIL-12 over time. A) Plasma concentration vs. time for rHuIL-12 at 2, 5, 10, 12, 15 and 20 μg doses in the FIH study. B) Plasma concentration vs. time for rHuIL-12 (12 μg) and for IFN-γ and CXCL10 in subjects treated with rHuIL-12 at 12 μg in the phase 1b expansion study.Back to article page